PortalPublikationenClinical impact of human Jurkat T-cell-line-derived antithym...

Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.

Standard

Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. / Ayuketang Ayuk, Francis; Perez-Simon, José A; Shimoni, Avichai; Sureda, Anna; Zabelina, Tatjana; Schwerdtfeger, Rainer; Martino, Rodrigo; Sayer, Herbert Gottfried; Alegre, Adrián; Lahuerta, Juan-José; Atanackovic, Djordje; Wolschke, Christine; Nagler, Arnon; Zander, Axel R.; Miguel, San; Kröger, Nicolaus; Kröger, Nicolaus.

in: HAEMATOLOGICA, Jahrgang 93, Nr. 9, 9, 2008, S. 1343-1350.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Ayuketang Ayuk, F, Perez-Simon, JA, Shimoni, A, Sureda, A, Zabelina, T, Schwerdtfeger, R, Martino, R, Sayer, HG, Alegre, A, Lahuerta, J-J, Atanackovic, D, Wolschke, C, Nagler, A, Zander, AR, Miguel, S, Kröger, N & Kröger, N 2008, 'Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.', HAEMATOLOGICA, Jg. 93, Nr. 9, 9, S. 1343-1350. https://doi.org/10.3324/haematol.12665

APA

Ayuketang Ayuk, F., Perez-Simon, J. A., Shimoni, A., Sureda, A., Zabelina, T., Schwerdtfeger, R., Martino, R., Sayer, H. G., Alegre, A., Lahuerta, J-J., Atanackovic, D., Wolschke, C., Nagler, A., Zander, A. R., Miguel, S., Kröger, N., & Kröger, N. (2008). Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. HAEMATOLOGICA, 93(9), 1343-1350. [9]. https://doi.org/10.3324/haematol.12665

Vancouver

Ayuketang Ayuk F, Perez-Simon JA, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R et al. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation. HAEMATOLOGICA. 2008;93(9):1343-1350. 9. https://doi.org/10.3324/haematol.12665

Bibtex

@article{6329dffb209d4e24a7f14ac82c373376,
title = "Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.",
abstract = "BACKGROUND: Antithymocyte globulin or human Jurkat T-cell-line-derived antilymphocyte globulin is used in allogeneic stem cell transplantation to induce in vivo T-cell depletion to facilitate engraftment and lower graft-versus-host disease. In vitro studies suggest that antithymocyte globulin, besides causing T-cell depletion, has strong anti-myeloma activity. DESIGN AND METHODS: We evaluated the anti-myeloma activity of antilymphocyte globulin in a melphalan/fludarabine-based reduced intensity conditioning regimen as well as the incidence of graft-versus-host disease in 138 multiple myeloma patients who underwent allogeneic stem cell transplantation with (n=79) or without (n=59) antilymphocyte globulin. RESULTS: Leukocyte and platelet engraftment were faster in the group not receiving antilymphocyte globulin (13 vs. 16 days, p",
author = "{Ayuketang Ayuk}, Francis and Perez-Simon, {Jos{\'e} A} and Avichai Shimoni and Anna Sureda and Tatjana Zabelina and Rainer Schwerdtfeger and Rodrigo Martino and Sayer, {Herbert Gottfried} and Adri{\'a}n Alegre and Juan-Jos{\'e} Lahuerta and Djordje Atanackovic and Christine Wolschke and Arnon Nagler and Zander, {Axel R.} and San Miguel and Nicolaus Kr{\"o}ger and Nicolaus Kr{\"o}ger",
year = "2008",
doi = "10.3324/haematol.12665",
language = "Deutsch",
volume = "93",
pages = "1343--1350",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "9",

}

RIS

TY - JOUR

T1 - Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.

AU - Ayuketang Ayuk, Francis

AU - Perez-Simon, José A

AU - Shimoni, Avichai

AU - Sureda, Anna

AU - Zabelina, Tatjana

AU - Schwerdtfeger, Rainer

AU - Martino, Rodrigo

AU - Sayer, Herbert Gottfried

AU - Alegre, Adrián

AU - Lahuerta, Juan-José

AU - Atanackovic, Djordje

AU - Wolschke, Christine

AU - Nagler, Arnon

AU - Zander, Axel R.

AU - Miguel, San

AU - Kröger, Nicolaus

AU - Kröger, Nicolaus

PY - 2008

Y1 - 2008

N2 - BACKGROUND: Antithymocyte globulin or human Jurkat T-cell-line-derived antilymphocyte globulin is used in allogeneic stem cell transplantation to induce in vivo T-cell depletion to facilitate engraftment and lower graft-versus-host disease. In vitro studies suggest that antithymocyte globulin, besides causing T-cell depletion, has strong anti-myeloma activity. DESIGN AND METHODS: We evaluated the anti-myeloma activity of antilymphocyte globulin in a melphalan/fludarabine-based reduced intensity conditioning regimen as well as the incidence of graft-versus-host disease in 138 multiple myeloma patients who underwent allogeneic stem cell transplantation with (n=79) or without (n=59) antilymphocyte globulin. RESULTS: Leukocyte and platelet engraftment were faster in the group not receiving antilymphocyte globulin (13 vs. 16 days, p

AB - BACKGROUND: Antithymocyte globulin or human Jurkat T-cell-line-derived antilymphocyte globulin is used in allogeneic stem cell transplantation to induce in vivo T-cell depletion to facilitate engraftment and lower graft-versus-host disease. In vitro studies suggest that antithymocyte globulin, besides causing T-cell depletion, has strong anti-myeloma activity. DESIGN AND METHODS: We evaluated the anti-myeloma activity of antilymphocyte globulin in a melphalan/fludarabine-based reduced intensity conditioning regimen as well as the incidence of graft-versus-host disease in 138 multiple myeloma patients who underwent allogeneic stem cell transplantation with (n=79) or without (n=59) antilymphocyte globulin. RESULTS: Leukocyte and platelet engraftment were faster in the group not receiving antilymphocyte globulin (13 vs. 16 days, p

U2 - 10.3324/haematol.12665

DO - 10.3324/haematol.12665

M3 - SCORING: Zeitschriftenaufsatz

VL - 93

SP - 1343

EP - 1350

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 9

M1 - 9

ER -